Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) Free cash flow margin
Solventum Corporation's free cash flow margin over the twelve months to 30 June 2026 was −1.42%, down 1.3 percentage points from fiscal 2025 (−0.12%). That is below the Medical Instruments & Supplies industry median of 1.61% and below the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | −0.12% | (9.87) |
| FY2024 | 9.75% | (10.07) |
| FY2023 | 19.8% | 2.26 |
| FY2022 | 17.6% | — |
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| ALGN Align Technology, Inc. compare | 16.3% |
| COO The Cooper Companies, Inc. compare | 16.0% |
| ALC Alcon compare | 14.7% |
| RGEN Repligen Corporation compare | 14.1% |
| WST West Pharmaceutical Services, Inc. compare | 13.1% |
| ATR AptarGroup, Inc. compare | 8.00% |
| BAX Baxter International Inc. compare | 7.11% |
| AVTR Avantor, Inc. compare | 6.93% |
| SOLV Solventum Corporation | −1.42% |
| Medical Instruments & Supplies industry median | 1.61% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on SOLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement